BrightAccountsProduction v1.0.0 v1.0.0 2024-01-01 The company was not dormant during the period The company was trading for the entire period Unaudited Accounts Specialist medical services 1 September 2025 1 1 10505928 2024-12-31 10505928 2023-12-31 10505928 2022-12-31 10505928 2024-01-01 2024-12-31 10505928 2023-01-01 2023-12-31 10505928 uk-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 10505928 uk-curr:PoundSterling 2024-01-01 2024-12-31 10505928 uk-bus:FullAccounts 2024-01-01 2024-12-31 10505928 uk-bus:Director1 2024-01-01 2024-12-31 10505928 uk-bus:Director2 2024-01-01 2024-12-31 10505928 uk-bus:RegisteredOffice 2024-01-01 2024-12-31 10505928 uk-bus:Agent1 2024-01-01 2024-12-31 10505928 uk-core:ShareCapital 2024-12-31 10505928 uk-core:ShareCapital 2023-12-31 10505928 uk-core:RetainedEarningsAccumulatedLosses 2024-12-31 10505928 uk-core:RetainedEarningsAccumulatedLosses 2023-12-31 10505928 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-12-31 10505928 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2023-12-31 10505928 uk-bus:FRS102 2024-01-01 2024-12-31 10505928 uk-core:WithinOneYear 2024-12-31 10505928 uk-core:WithinOneYear 2023-12-31 10505928 uk-core:AfterOneYear 2024-12-31 10505928 uk-core:AfterOneYear 2023-12-31 10505928 uk-core:Share-basedArrangement1 2024-01-01 2024-12-31 10505928 2024-01-01 2024-12-31 10505928 uk-bus:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
Mk Colorectal Ltd.
 
Directors' Report and Unaudited Financial Statements
 
for the financial year ended 31 December 2024
Mk Colorectal Ltd.
DIRECTORS AND OTHER INFORMATION

 
Directors Richard O'Hara
Nicola O'Hara
 
 
Company Registration Number 10505928
 
 
Registered Office Cuckoo Wharf
427 Lichfield Road
Birmingham
B6 7SS
United Kingdom
 
 
Business Address 10 Butterton Gardens
Broughton
Milton Keynes
MK10 7BU
 
 
Accountants Capitax & Co (Tax Consultants) Ltd
Cuckoo Wharf
427 Lichfield Road
Birmingham
West Midlands
B6 7SS
GB



Mk Colorectal Ltd.
DIRECTORS' REPORT
for the financial year ended 31 December 2024

 
The directors present their report and the unaudited financial statements for the financial year ended 31 December 2024.
 
Principal Activity
Specialist medical services
     
Directors
The directors who served during the financial year are as follows:
     
Richard O'Hara
Nicola O'Hara
   
There were no changes in shareholdings between 31 December 2024 and the date of signing the financial statements.
     
In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.
     
Political Contributions
The company did not make any disclosable political donations in the current financial year.
     
Statement of Directors' Responsibilities
     
The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.
     
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:
select suitable accounting policies and apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
     
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
     
Special provisions relating to small companies
The above report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.
     
     
On behalf of the board
     
     
___________________________
Richard O'Hara
Director
     
5 September 2025



Mk Colorectal Ltd.
PROFIT AND LOSS ACCOUNT
for the financial year ended 31 December 2024
2024 2023
Notes £ £

Turnover 124,184 112,227
───────── ─────────
Gross profit 124,184 112,227
 
Administrative expenses (42,533) (37,906)
───────── ─────────
Profit before taxation 81,651 74,321
 
Tax on profit 4 (17,888) (15,503)
───────── ─────────
Profit for the financial year 63,763 58,818
───────── ─────────
Total comprehensive income 63,763 58,818
    ═════════   ═════════



Mk Colorectal Ltd.
Company Registration Number: 10505928
BALANCE SHEET
as at 31 December 2024

2024 2023
Notes £ £
 
Current Assets
Debtors 5 5,140 9,206
Cash and cash equivalents 26,734 18,395
───────── ─────────
31,874 27,601
───────── ─────────
Creditors: amounts falling due within one year 6 (19,044) (16,680)
───────── ─────────
Net Current Assets 12,830 10,921
───────── ─────────
Total Assets less Current Liabilities 12,830 10,921
 
Creditors:
amounts falling due after more than one year 7 (3,815) (2,669)
───────── ─────────
Net Assets 9,015 8,252
═════════ ═════════
 
Capital and Reserves
Called up share capital 100 100
Retained earnings 8,915 8,152
───────── ─────────
Equity attributable to owners of the company 9,015 8,252
═════════ ═════════
 
These financial statements have been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.
           
For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006.
           
The directors confirm that the members have not required the company to obtain an audit of its financial statements for the financial year in question in accordance with section 476 of the Companies Act 2006.
           
The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its profit and loss for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
           
Approved by the Board and authorised for issue on 5 September 2025 and signed on its behalf by
           
           
________________________________          
Richard O'Hara          
Director          
           



Mk Colorectal Ltd.
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 December 2024

   
1. General Information
 
Mk Colorectal Ltd. is a company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 10505928. The registered office of the company is Cuckoo Wharf, 427 Lichfield Road, Birmingham, B6 7SS, United Kingdom. Specialist medical services The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial year ended 31 December 2024 have been prepared in accordance with the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland (FRS 102) issued by the Financial Reporting Council and in accordance with the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Cash flow statement
The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Borrowing costs
Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Share-based payments
The company issues equity-settled and cash-settled share-based payments to certain employees (including directors). Equity-settled share-based payments are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, together with a corresponding increase in equity, based upon the company's estimate of the shares that will eventually vest. Fair value is measured using the Black-Scholes Pricing Model. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations. Where the terms of an equity-settled transaction are modified, as a minimum an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the value of the transaction as a result of the modification, as measured at the date of modification. Where an equity-settled transaction is cancelled, it is treated as if it had vested on the date of the cancellation, and any expense not yet recognised for the transaction is recognised immediately. However, if a new transaction is substituted for the cancelled transaction, and designated as a replacement transaction on the date that it is granted, the cancelled and new transactions are treated as if they were a modification of the original transaction, as described in the previous paragraph. For cash-settled share-based payments, a liability equal to the portion of the goods and services received is recognised at the current fair value determined at each balance sheet date.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.
 
Taxation and deferred taxation
Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
       
3. Employees
 
The average monthly number of employees, including directors, during the financial year was 1, (2023 - 1).
 
  2024 2023
  Number Number
 
Directors 1 1
  ═════════ ═════════
       
4. Tax on profit
  2024 2023
  £ £
(a)     Analysis of charge in the financial year
 
Current tax:
Corporation tax at 25.00% (2023 - 25.00%) (Note 4 (b)) 17,888 15,503
  ═════════ ═════════
 
(b)     Factors affecting tax charge for the financial year
 
The tax assessed for the financial year differs from the standard rate of corporation tax in United Kingdom 25.00% (2023 - 25.00%). The differences are explained below:
  2024 2023
  £ £
 
Profit taxable at 25.00% 81,651 74,321
  ═════════ ═════════
Profit before tax
multiplied by the standard rate of corporation tax
in United Kingdom at 25.00% (2023 - 25.00%) 20,413 18,580
Effects of:
Marginal Tax Relief (2,525) (3,077)
  ───────── ─────────
Total tax charge for the financial year (Note 4 (a)) 17,888 15,503
  ═════════ ═════════
 
       
5. Debtors 2024 2023
  £ £
 
Debtors 5,140 9,206
  ═════════ ═════════
       
6. Creditors 2024 2023
Amounts falling due within one year £ £
 
Taxation  (Note 8) 17,988 15,624
Accruals 1,056 1,056
  ───────── ─────────
  19,044 16,680
  ═════════ ═════════
       
7. Creditors 2024 2023
Amounts falling due after more than one year £ £
 
Directors' loan accounts 3,815 2,669
  ═════════ ═════════
 
       
8. Taxation 2024 2023
  £ £
 
Creditors:
Corporation tax 17,888 15,503
PAYE / NI 100 121
  ───────── ─────────
  17,988 15,624
  ═════════ ═════════
           
9. Share-based payments
 
Equity-settled share-based payments
 
The company has no share option scheme for employees.
       
10. Capital commitments
 
The company had no material capital commitments at the financial year-ended 31 December 2024.
   
11. Directors' advances, credits and guarantees
 
During the financial year, the company made no loan(s) to Director(s).
   
12. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.